基线肿瘤负荷与新一代免疫肿瘤药物治疗结局的关联
结果显示,较低的基线肿瘤负荷与更好的客观缓解率、无进展生存期和总生存期显著相关,且在多因素分析中为独立预后因素。
要点
- 基线肿瘤负荷较低者接受NGIOs治疗后的缓解率更高。
- BTS最低四分位组12个月PFS率为26%、OS率为56%,最高四分位组分别为3%和24%。
- 基线肿瘤负荷是PFS和OS的独立预后因素。
核心结论
- 在接受新型免疫治疗的实体瘤患者中,较低的基线肿瘤负荷与更好的治疗结局相关。
主要发现
- 中位BTS为79 mm,中位TTB为212 mm。
- 客观缓解率与BTS四分位(p < 0.001)及TTB四分位(p = 0.006)显著相关,缓解率随肿瘤负荷四分位降低而逐渐升高。
- 无进展生存期(PFS)(p = 0.001)和总生存期(OS)(p < 0.001)均与BTS四分位显著相关;BTS最低四分位组12个月无进展比例为26%、生存比例为56%,最高四分位组分别为3%和24%。
- TTB与OS显著相关(P = 0.01),与PFS的相关性为临界显著(p = 0.07)。
- 多因素分析证实基线负荷作为连续变量时,BTS(PFS p = 0.001,OS p < 0.001)和TTB(PFS p = 0.007,OS p < 0.001)均与PFS和OS独立相关。
临床怎么用
- 在启动新一代免疫肿瘤药物治疗前评估基线肿瘤负荷,可能有助于预后分层和治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Baseline tumour burden is a prognostic factor for patients with melanoma and non-small-cell lung cancer treated with immunotherapy. However, no data are available on its role in other solid tumours, nor for treatment with next-generation immunoncology agents (NGIOs). METHODS: We reviewed data of patients with any solid tumour consecutively treated at our institution from August 2014 to March 2019, who received ≥1 dose of immune checkpoint inhibitor and/or NGIO within phase 1 trials. Baseline tumour burden was calculated as ∑i Response Evaluation Criteria in Solid Tumours 1.1 baseline target lesions (baseline tumour size [BTS]) or as sum of all measurable baseline lesions (total tumour burden [TTB]); the impact of both parameters on treatment outcomes was investigated. RESULTS: One hundred fifty patients were included in the analysis. Median BTS and TTB were 79 mm and 212 mm, respectively. Objective response rate was found significantly associated with BTS (p < 0.001) and TTB quartiles (p = 0.006), with response rates progressively increasing with decreasing tumour burden quartiles. Both progression-free survival (PFS) (p = 0.001) and overall survival (OS) (p < 0.001) were significantly associated with BTS quartiles, with 26% of the patients progression-free and 56% alive at 12 months in the lower BTS quartile, compared with 3% and 24%, respectively, in the upper quartile. TTB was also significantly associated with OS (P = 0.01) and borderline-significant for PFS (p = 0.07). Multivariate analysis confirmed that baseline burden, also considered as continuous variable, is independently associated with PFS and OS, when assessed with BTS (p = 0.001 and p < 0.001) and TTB (p = 0.007 and p < 0.001). CONCLUSIONS: Lower baseline tumour burden is associated with better outcomes in patients with cancer treated with novel immunotherapies.
引用
- Tarantino P, Marra A, Gandini S, et al. Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents. Eur J Cancer. 2020. PMID: 32979647. doi:10.1016/j.ejca.2020.08.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。